We thank Dr Weinshenker for the opportunity to expand on our commentary on the value of plasma exchange in neurological disorders (Neuroimmunology: Assessing the value of plasma exchange in neurology. Nat. Rev. Neurol. 7, 309-310; 2011) 1 in which editorial constraints prevented us from referring to all the randomized trials conducted in the field including his and our own. We acknowledge that his crossover trial of plasma exchange in 22 patients with a variety of different acute demyelinating diseases provides the best available evidence for the management of this group of patients (Plasmapheresis: are bigger studies necessarily better? Nat. Rev. Neurol. doi:10.1038/ nrneurol.2011.59-c1).
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2,3 The discovery of anti-aquaporin-4 anti bodies in neuromyelitis optica has shown that acute demyelinating AUTHORS' REPLY Plasma exchange: are bigger studies necessarily better?
Richard Hughes & Hans-Peter Hartung diseases have a heterogeneous pathology. It will now be important to obtain further evidence for the efficacy of plasma exchange in different subgroups. We agree that small trials are useful and necessary in rare conditions and that the evidence of two or more trials can be synthesized with careful meta-analysis as commonly done in Cochrane reviews. 
